StockNews.AI
VRPX
StockNews.AI
165 days

Virpax Looking to Use MET to Develop Intranasal COVID Vaccine

1. Virpax explores using Molecular Envelope Technology for an mRNA COVID vaccine. 2. This technology is already utilized in their existing products Envelta and NobrXiol.

2m saved
Insight
Article

FAQ

Why Bullish?

The potential application of MET in a COVID vaccine can diversify VRPX's portfolio, reminiscent of how other biotech firms surged post vaccine developments.

How important is it?

The exploration of mRNA technology represents a significant strategic pivot that could enhance market perception and product offerings.

Why Long Term?

Successful implementation could establish VRPX as a key player in the COVID response, similar to past instances where biotech innovations led to sustained growth.

Related Companies

MRNAPFEBNTX
BERWYN, Pa.--(BUSINESS WIRE)--Virpax Pharmaceuticals, Inc. (Nasdaq: VRPX) (“Virpax” or the “Company”), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS) disorders and anti-viral barrier indications, is looking to use Molecular Envelope Technology (MET) or a similar technology to deliver a mRNA COVID vaccine. Virpax currently uses its MET for Envelta (NES100) and NobrXiol (VRP324). The Company will look t.

Related News